MET amplification leads to overexpression or constitutive kinase activation via multiplication of the MET gene and synthesis of MET protein in excess; thus, the level of gene amplification may act as an oncogenic driver in patients with NSCLC (12). The gene discussed is MET; the disease is non-small cell lung carcinoma.